Sort
48,018 grants matching “immunotherapy”
Pharmacodynamically directed targeted therapy for leukemia
$683,472John C Byrd · University Of Cincinnati · R01 · FY2025 · CA
Structural and functional characterization of T and NK cell receptors
$683,452Peter D. Sun · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Pediatric AIDS Clinical Trials Unit
$683,386Duke University · U01 · FY2002 · AI
High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
$683,382Udai S Kammula · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
CAR-T cell treatment of CNS Autoimmunity
$683,358Gregory Wu · Washington University · R01 · FY2023 · AI
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
$683,274David M. Lewinsohn · Oregon Health & Science University · R01 · FY2021 · AI
MECHANISMS OF CHRONIC HEPATITIS B INFECTION
$683,213Vaccine Research Institute Of San Diego · R01 · FY2004 · AI
Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
$683,099Nduka Mgbechinyere Amankulor · University Of Pennsylvania · R37 · FY2023 · CA
Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining
$683,089Saad Nadeem · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Cancer Pharmacology
$683,087Lorraine J Gudas · Weill Medical Coll Of Cornell Univ · T32 · FY2023 · CA
Immune Mechanisms in Ocular Graft versus Host Disease
$682,870Victor L Perez · University Of Miami School Of Medicine · R01 · FY2016 · EY
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
$682,855Stephen C. Dreskin · University Of Colorado Denver · R01 · FY2023 · AI
Winship National Clinical Trials Network Lead Academic Participating Site
$682,746Nabil F Saba · Emory University · UG1 · FY2025 · CA
Immunogenetic determinants of cancer risk
$682,727Robert M Samstein · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies
$682,709Ronald J Falk · Univ Of North Carolina Chapel Hill · R01 · FY2023 · DK
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$682,689David A. Hafler · Yale University · R01 · FY2025 · CA
CAR-T cell treatment of CNS Autoimmunity
$682,626Gregory Wu · Washington University · R01 · FY2024 · AI
Translating buccal nanocytology for lung cancer screening into clinical practice
$682,587Vadim Backman · Northwestern University · R01 · FY2024 · CA
Therapeutic targeting MDSC-mediated immune suppression in cancer
$682,585Yulia Nefedova · Wistar Institute · R01 · FY2023 · CA
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
$682,539Daniel B Stetson · University Of Washington · R01 · FY2023 · CA
Development of multinuclear MRI for image guided therapy of glioma patients
$682,470Ovidiu C Andronesi · Massachusetts General Hospital · R01 · FY2024 · CA
Development of quantitative optical tools to continuously monitor cerebral autoregulation, blood flow, oxygenation and inflammation during pediatric extracorporeal life support
$682,467David Richard Busch · Ut Southwestern Medical Center · R01 · FY2022 · NS
Project 1: Transgenic TCR-mediated tumor therapy
$682,429Philip D Greenberg · University Of Washington · P01 · FY2021 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$682,315Katerina Abigail Politi · Yale University · R01 · FY2021 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$682,247Meghan E. Sise · Massachusetts General Hospital · R01 · FY2024 · DK